Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease

Imagem de Miniatura
Arquivos
art_LOPES_Plasma_von_Willebrand_factor_as_a_predictor_of_2011.PDF (449.35 KB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRAS DIVULG CIENTIFICA
Autores
MAEDA, N. Y.
RICH, S.
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.44, n.12, p.1269-1275, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Biomarkers have been identified for pulmonary arterial hypertension, but are less well defined for specific etiologies such as congenital heart disease-associated pulmonary arterial hypertension (CHDPAH). We measured plasma levels of eight microvascular dysfunction markers in CHDPAH, and tested for associations with survival. A cohort of 46 inoperable CHDPAH patients (age 15.0 to 60.2 years, median 33.5 years, female: male 29: 17) was prospectively followed for 0.7 to 4.0 years (median 3.6 years). Plasma levels of von Willebrand factor antigen (VWF:Ag), tissue plasminogen activator (t-PA) and its inhibitor (PAI-1), P-selectin, reactive C-protein, tumor necrosis factor alpha, and interleukin-6 and -10 were measured at baseline, and at 30, 90, and 180 days in all subjects. Levels of six of the eight proteins were significantly increased in patients versus controls (13 to 106% increase, P < 0.003). Interleukin-10 level was 2.06 times normal (P = 0.0003; Th2 cytokine response). Increased levels of four proteins (t-PA, PAI-1, P-selectin, and interleukin-6) correlated with disease severity indices (P < 0.05). Seven patients died during follow-up. An average VWF: Ag (mean of four determinations) above the level corresponding to the 95th percentile of controls (139 U/dL) was independently associated with a high risk of death (hazard ratio = 6.56, 95% CI = 1.46 to 29.4, P = 0.014). Thus, in CHDPAH, microvascular dysfunction appears to involve Th2 inflammatory response. Of the biomarkers studied, plasma vWF:Ag was independently associated with survival.
Palavras-chave
Pulmonary hypertension, Congenital heart disease, Eisenmenger syndrome, Endothelial dysfunction, von Willebrand factor, Th2 cytokine response
URI
https://observatorio.fm.usp.br/handle/OPI/22546
Referências
  1. Rubens C, 2001, CHEST, V120, P1562, DOI 10.1378/chest.120.5.1562
  2. Daley E, 2008, J EXP MED, V205, P361, DOI 10.1084/jem.20071008
  3. Uchiyama T, 2000, ARTERIOSCL THROM VAS, V20, P1155
  4. Ware LB, 2001, CRIT CARE MED, V29, P2325, DOI 10.1097/00003246-200112000-00016
  5. Pinto RFA, 2004, CARDIOVASC PATHOL, V13, P268, DOI 10.1016/j.carpath.2004.06.003
  6. Friedman R, 1997, CIRCULATION, V96, P2782
  7. Kawut SM, 2005, CHEST, V128, P2355, DOI 10.1378/chest.128.4.2355
  8. Folsom AR, 1997, CIRCULATION, V96, P1102
  9. Blyth KG, 2007, EUR RESPIR J, V29, P737, DOI 10.1183/09031936.00095606
  10. Tuder RM, 1999, AM J RESP CRIT CARE, V159, P1925
  11. Bull TM, 2003, THROMB HAEMOSTASIS, V90, P698, DOI 10.1160/TH03-04-0251
  12. Diller GP, 2008, CIRCULATION, V117, P3020, DOI 10.1161/CIRCULATIONAHA.108.769646
  13. Dimopoulos K, 2010, CIRCULATION, V121, P20, DOI 10.1161/CIRCULATIONAHA.109.883876
  14. Budhiraja R, 2004, CIRCULATION, V109, P159, DOI 10.1161/01.CIR.0000102381.57477.50
  15. Morange PE, 2004, CIRCULATION, V109, P1343, DOI 10.1161/01.CIR.0000120705.55512.EC
  16. Shitrit D, 2002, CHEST, V122, P1674, DOI 10.1378/chest.122.5.1674
  17. White RJ, 2007, AM J PHYSIOL-LUNG C, V293, pL583, DOI 10.1152/ajplung.00321.2006
  18. GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403
  19. Tsai AW, 2002, AM J MED, V113, P636, DOI 10.1016/S0002-9343(02)01345-1
  20. [Anonymous], 2002, AM J RESP CRIT CARE, V166, P111
  21. GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402
  22. RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733
  23. Nagaya N, 1999, AM J RESP CRIT CARE, V160, P487
  24. Sakamaki F, 2000, CIRCULATION, V102, P2720
  25. MASUYAMA T, 1986, CIRCULATION, V74, P484
  26. Barreto AC, 2008, BRAZ J MED BIOL RES, V41, P657
  27. Borgeson D D, 1996, J Am Soc Echocardiogr, V9, P832, DOI 10.1016/S0894-7317(96)90475-7
  28. CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202
  29. Gorlach A, 2005, THROMB HAEMOSTASIS, V93, P1168, DOI 10.1160/TH05-01-0006
  30. HATTORI R, 1987, CIRCULATION S, V78, P117
  31. Lopes AA, 2000, AM HEART J, V139, P618, DOI 10.1016/S0002-8703(00)90038-3
  32. Oya H, 2000, HEART, V84, P53, DOI 10.1136/heart.84.1.53
  33. PALEOLOG EM, 1990, BLOOD, V75, P688
  34. PENNY WF, 1991, CIRCULATION, V83, P1630
  35. Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440
  36. RABINOVITCH M, 1987, CIRCULATION, V76, P1043
  37. RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771
  38. TAKAHASHI H, 1992, AM J HEMATOL, V41, P32, DOI 10.1002/ajh.2830410107
  39. WAGNER DD, 1991, MAYO CLIN PROC, V66, P621
  40. ZAVOICO GB, 1989, J IMMUNOL, V142, P3993

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31